JP Morgan Live: Biotech's eighteen-like martial arts

Influenced by COVID-19, the annual JP Morgan Healthcare Conference was held online from January 11 to 14, 2021, the first time the summit has been held online since the 39th session.
Biotech's motivation on JP Morgan is simple and straightforward - looking for potential opportunities for collaboration from money or projects, if the giant's bosses are trying to calm investor confidence, calm board sentiment and perhaps even make a show.
at this year's JP Morgan conference, what unique skills did many Biotech leaders demonstrate? This article lists 10 of these companies from a large number of speeches for everyone to enjoy.
Vertex: "I'm the Only One" in Cystic Fibrosis is the prototype of the best-selling "Billion Dollar Molecule."
the company, founded in 1989, started with $10 million and was founded by Joshua Borg, a chemist from Merca East.
is now ranked 39th among the world's top 50 pharmaceutical companies, with revenues of more than $4 billion in 2020.
unique stunt that underpinned Vertex's transformation from a Biotech to Bioharma is one of several of the company's heavyweight products in the field of cystic fibrosis.
cystic fibrosis is an endosomal invisible genetic disease that, although rare in Asian populations, has a higher incidence in North America, Europe and Australia, affecting more than 75,000 people.
three cystic fibrosis drugs developed by the company cover almost the vast majority of patients.
Ceo Reshma Kewalramani, formerly the company's CMO chief medical officer, replaced Jeffrey Leiden, who was promoted from CEO to chairman in April 2020.
Kewalraman told JP Morgan that in addition to promoting triple CF treatment Trikafta globally and strengthening existing product pipeline mid- to late-stage product development programs, such as gene therapy CTX001 developed in partnership with CRISPR, it hopes to find candidates to complement its product line.
Jazz: "Out" by mental illness, the lungs can also "take their hands out" Jazz Pharmaceuticals, which was founded in 2003 and has grown into a company with annual revenues of more than $2.1bn.
its products are more interesting for adaptation certificates, such as symptoms of drowsiness and daytime excessive drowsiness, psychotic drugs for obsessive compulsive disorder treatment and schizophrenia, and cancer drugs for small cell lung cancer.
bruce Cozadd, CEO of Bruce Cozadd, said on JP Morgan that five more products will be available by the end of 2022 and that they will contribute more than 50 percent of the company's total revenue over the next two years.
: At worst, a well-known vaccine company was affected by COVID-19, and few people today know that Moderna has been so successful in developing the mRNA vaccine.
fact, Moderna didn't take long to set up, and today it's only 10 years old.
ceo, Stéphane Bancel, said in a JPM speech that Moderna's image had been greatly enhanced by the success of the COVID-19 vaccine and that the company was on track to usher in an inflection year in 2021.
has received $11.7 billion in orders for COVID vaccines, second only to Pfizer, and is expected to be among the top vaccine makers this year, with 600 million to 1 billion doses of COVID vaccine planned for 2021, according to Bancel.
There are also a number of drug candidates for influenza, Zika virus, respiratory syncytial virus (RSV) and other diseases, such as the cytocytovirus vaccine (mRNA-1647), which will enter Phase III this year, which is expected to bring a peak in sales of $2 billion to $5 billion.
"the future of Moderna, the worst-case scenario is to become a very important vaccine company, which we don't want to see."
"This is probably the most Versailles literary verse on JP Morgan."
but Beancel is still obsessively explaining to investors that Moderna doesn't want to be a company known for a technology or a drug, but rather a platform company.
BioNTech: BioNTech, which is "full power" for the production of the new mRNA vaccine, said it aims to produce 2 billion doses of comirnaty, a new mRNA vaccine developed in partnership with Pfizer, by 2021, up from its previous target of 1.3 billion doses.
increase will rely on six global production sites partnered by BioNTech and Pfizer, including the Marburg, Germany, site, which will open in February, with an annual production capacity of 750 million doses.
addition to the BioNTech Marburg site, BioNTech plans to introduce six doses of vaccine vials per bottle to simplify storage and expand new suppliers and CFOs to expand labels for children, pregnant women and other sub-populations.
In addition to expanding patient coverage for the vaccine, BioNTech plans to conduct further stability testing of its current formulation (subject to strict cold chain requirements), polyethyl glycol-free formulations (which may be associated with side effects), and more stable injection formulations.
about COVID vaccine manufacturers like Novovax and Catalen, who have also spoken out about their strong vaccine development capabilities and capacity advantages at JP Morgan.
Bluebird Bio: Business Spin-Off, Genetic Diseases and Oncology Independently operated Bluebird Bio announced on JP Morgan that it would split into two publicly traded pharmaceutical companies, one dedicated to treating severe genetic diseases (Bluebird Bio) and the other dedicated to treating cancer (as yet unnamed).
Nick Leschly, the current CEO of Nick Leschly, will lead the as-yet-unnamed oncology company and serve as executive chairman of Bluebird Bio, with Andrew Obenshain, now president of the Genetic Diseases business, as CEO of Bluebird Bio.
Nick Leschly, an independent company, said the division of the two businesses could double their respective businesses, driving strategic and operational goals.
bluebird biotech has developed gene and cell therapies for severe genetic diseases and oncology, and its first commercial product has now been approved in Europe.
Fujifilm: Fujifilm, which doubles performance with healthcare systems and bioDMO, is a company that has crossed the border from other industries into the biopharmaceutical sector.
's CEO, Kenji Sukeno, said Fujifilm aims to nearly double its healthcare revenue to Y1, 000bn ($9.3bn) by 2025 and rely heavily on its fast-growing healthcare systems and bioCDMO business.
Sukeno said revenue from its healthcare systems is expected to surge to about 500 billion yen ($4.6 billion) by 2021, assuming Fujifilm buys Theachi's diagnostic imaging-related business for $1.7 billion.
, Fujifilm hopes its bioDMO business will reach 200 billion yen ($1.8 billion) by 2024.
Legendary Creatures: The CAR-T Therapy Legendary Creatures from China, originally owned by Kingsley and listed on NASDAQ in June 2020, are becoming a bridge between East and West in the global cell therapy world.
as early as December 2017, Johnson and Johnson Medical (Jansen) introduced legendary biodevelopment target BCMA's CAR-T therapy cilacabtagene autoleucel (cilta-cel) with an upfront payment of $350 million and subsequent milestone payments of $110 million.
December 2020, cilta-cel has begun rolling the submission of a Biological Products Licensing Application (BLA) at the FDA, which is expected to be approved in the second half of 2021.
also plans to submit a cilta-cel listing permit application (MAA) in Europe in the first half of 2021 and a Chinese BLA in the second half of the year.
Wanchun Medicine: Wanchun Pharmaceuticals, which is in the process of layout marketing system for China and the United States, will enter the commercialization phase in 2021.
the product was recognized as a "breakthrough treatment variety" by China's NMPA and the FDA in the field of severe neutral granulocyte reduction (CIN) in 2021, the first major breakthrough in treatment standards and clinical benefits in the field in more than 30 years.
the company hopes to make Punablin into a skeleton drug for cancer immunotherapy, which is used in the likes of classic radiotherapy and the recent rise of PD-1/PD-L1/CTLA-4.
's CEO, Dr. Huang Qi, said the Chinese market is expected to exceed RMB10 billion/year by 2030, the U.S. market is more than $5 billion/year, and the U.S. marketing system is being laid out.
Yasheng Pharma: 2020 the world's "orphan medicine" king Yasheng Pharmaceutical Dr. Yang Dajun at the JP Morgan Conference introduced the company's many landmark progress, the most notable of which is that the company in 2020 a total of 9 orphan drug certification, not only the history of Chinese pharmaceutical companies, but also the world's highest pharmaceutical companies in 2020 single year.
the company's start-up technology is also more special, with its apoptosis and protein-protein interaction two scientific mechanisms, its development of the drug "global innovation" strategic effects gradually appear, its first NDA drug HQP1351 has been included in the China Drug Administration priority review, is expected to be approved for market this year.
Baiji Shenzhou: Holding 12 commercial products of the giant Biotech Baiji Shenzhou every major transaction event brush screen behind, we pay more attention to the company will be its own products after the out of the out of how much money, or spend a lot of money to introduce what platform and what technology.
the introduction of mature products in order to add code to the commercial sales system is often overlooked by us.
at the JP Morgan conference, CEO O'Reilly said the state will have as many as 12 commercial products by 2021, with the exception of the Reilly-Zhu monolith and Zebutini, which have already entered the health insurance catalog, which are self-developed, and other products are mainly imported from deals with companies such as Xinji, Amgen and Baateur.
's huge annual investment in research and development has been amazed by its domestic peers, while the availability of commercialized returns has been questioned by some investors.
Wu Xiaobin, china's CEO with a sales representative background, can renew his commercial talent in Baiji Shenzhou? With more than a dozen drugs entering the market, it is the mule is a horse, the test of whether Baiji Shenzhou can change from Biotech to pharmaceutical giants is the time.